Top news of the week: 23.03.2022.
Startups
Biotech Bears: Jumping A Lower Bar Or A Higher One?
Biotech sentiment is super bearish today, as the sector has been crushed over the last year. There’s blood in the water, especially for small and mid-cap players, and everyone’s looking for ...
Innovation Ecosystem: A Year Of Risk-Off Correlations
Misery loves company, and so it goes with the stock market for the innovation ecosystem these days. The general risk-off market environment has been crushing both the emerging tech and ...
Women-owned startups see record venture capital gains in Philly
But progress for funding women-founded companies has plateaued across the U.S. in recent years.
GSK partners with LifeMine as startups advance plans to make drugs from fungi
The deal, announced alongside a $175 million round, makes biotech entrepreneur Greg Verdine's startup the most well-funded among an emerging group of companies searching for drugs ...
He Left MIT At 22 To Solve A Problem Investors Didn’t Get. Now His Company Is Worth $6 Billion
Sajith Wickramasekara worked as a research assistant during his high school years and realized R&D relied too heavily on pens and paper. So he built Benchling, now worth $6 billion and ...
Insider identified 13 drug companies that are in a dangerous financial position and struggling to survive through 2022
Almost 500 SEC filings show these 13 biotechs facing "substantial doubts" about staying in business in the struggling market
Moderna CEO Stephane Bancel has sold more than $400 million of company stock during the pandemic
Moderna CEO Stephane Bancel has sold more than 2.8 million shares since January 2020 at a total value of more than $408 million.
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) the leading RNAi therapeutics company, announced today that it has separately filed suit in United States